Simon Grinshteyn
Family Medicine · Fort Myers, FLNPI 1841589173
Payments from drug & device makers
Across 93 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$214
- Amgen$146
- Otsuka America Pharmaceutical, Inc.$131
- Novo Nordisk$120
- Boehringer Ingelheim$119
- Antares Pharma, Inc.$118
- plus $879 from 24 others
What the payments were for
- Food & beverage$1,69498%
- Education$322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 13 | $214 |
| Amgen(2 entities) | 10 | $146 |
| Otsuka America Pharmaceutical, Inc. | 6 | $131 |
| Novo Nordisk | 6 | $120 |
| Boehringer Ingelheim | 6 | $119 |
| Antares Pharma, Inc. | 7 | $118 |
| AbbVie(2 entities) | 6 | $106 |
| Philips North America LLC | 3 | $103 |
| AstraZeneca | 4 | $63 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Organogenesis Inc. | 2 | $56 |
| Novartis | 3 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Abbott | 2 | $39 |
| GSK | 2 | $37 |
| Bayer | 1 | $33 |
| Dexcom, Inc. | 2 | $29 |
| Lundbeck LLC | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Insulet Corporation | 1 | $21 |
| KCI USA, Inc. | 1 | $20 |
| Smith+Nephew | 1 | $17 |
| Integra Lifesciences Corporation | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
| Medtronic | 1 | $12 |
| Phadia US Inc. | 1 | $11 |
How this compares
$1,726 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 82 | $81,881 |
| ZenpepLipase/Protease/Amylase | 19 | $67,987 |
| OzempicSemaglutide | 44 | $61,020 |
| MounjaroTirzepatide | 38 | $44,895 |
| EliquisApixaban | 35 | $40,134 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $36,343 |
| RybelsusSemaglutide | 12 | $20,250 |
| TrulicityDulaglutide | 17 | $20,062 |
| RexultiBrexpiprazole | 11 | $14,767 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 83 | $12,501 |
| EntrestoSacubitril/Valsartan | 14 | $10,546 |
| FarxigaDapagliflozin Propanediol | 11 | $6,658 |
| BrilintaTicagrelor | 13 | $6,536 |
| BelsomraSuvorexant | 14 | $6,254 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $5,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $119 | $81,88182 claims |
| Novo NordiskOzempic, Rybelsus | $120 | $81,26956 claims |
| Lilly USA, LLCMounjaro, Trulicity | $214 | $64,95755 claims |
| PfizerEliquis | $13 | $40,13435 claims |
| GSKTrelegy Ellipta | $37 | $36,34331 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $63 | $16,44038 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $131 | $14,76711 claims |
| NovartisEntresto | $49 | $10,54614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Fort Myers
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.